The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell Carcinoma
Abstract
Purpose: To review the biology of renal cell carcinoma (RCC) leading to vascular endothelial growth factor (VEGF) overexpression and the clinical results of VEGF blockade in metastatic RCC. Methods: A review of relevant published literature regarding VEGF, von Hippel-Lindau (VHL) gene inactivation and VEGF overexpression in RCC was performed. Further, a review of the mechanism, toxicity, and clinical development of VEGF-targeted therapy in metastatic RCC was undertaken. Results: VEGF is the major proangiogenic protein that exerts a biologic effect through interaction with cellular receptors. The majority of sporadic clear-cell RCC tumors are characterized by VHL tumor suppressor gene inactivation. The resulting VHL gene silencing leads to VEGF overexpression. An antibody to VEGF (bevacizumab) has demonstrated a significant prolongation of time to disease progression compared with placebo in patients with metastatic RCC. Small molecules with inhibitory effects against the VEGF receptor have undergone initial clinical testing in metastatic RCC with substantial objective response rates. Conclusion: Therapeutic targeting of VEGF in RCC has strong biologic rationale and preliminary clinical efficacy. Further investigation will determine the optimal timing, sequence, and utility of these agents in RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Dvorak, H. F., Brown, L. F., Detmar, M. J., & Dvořàk, A. M. (1995) · Europe PMC (PubMed Central) · Cited by 3,115
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Purification and Characterization of Hypoxia-inducible Factor 1
Wang, G. L., & Semenza, G. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.3.1230 · Cited by 2,073
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Lonser, R. R., Glenn, G. M., Walther, M., Chew, E. Y., Libutti, S. K., Linehan, W. M., & Oldfield, E. H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13643-4 · Cited by 1,600
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,573
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9700 · Cited by 1,529
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., & Abraham, J. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99049-6 · Cited by 1,476
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
Wang, G. L., & Semenza, G. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4304 · Cited by 1,468
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,241
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., & Ferrara, N. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35712-0 · Cited by 1,127
Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
Cheville, J. C., Lohse, C. M., Zincke, H., Weaver, A. L., & Blute, M. L. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200305000-00005 · Cited by 1,087
Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia
Levy, A. P., Levy, N. S., Wegner, S., & Goldberg, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13333 · Cited by 1,067
Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050
Interleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Gordon, M. S., Margolin, K., Talpaz, M., Sledge, G. W., Holmgren, E., Benjamin, R., Stalter, S., Shak, S., & Adelman, D. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.843 · Cited by 913
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F. E., Tai, Y.-T., Treon, S. P., Lin, B., Schlossman, R. L., Richardson, P., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 875
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
VEGF-receptor signal transduction
Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson-Welsh, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00193-2 · Cited by 864
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Dvorak, H. F., Nagy, J. A., Feng, D., Brown, L. F., & Dvorak, A. M. (1999) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-642-59953-8_6 · Cited by 743
Pertovaara, L., Kaipainen, A., Mustonen, T., Orpana, A., Ferrara, N., Saksela, O., & Alitalo, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37365-9 · Cited by 694
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
Knudson, A. G. (1986) · Annual Review of Genetics · doi:10.1146/annurev.ge.20.120186.001311 · Cited by 559
Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., & Iliopoulos, O. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80096-9 · Cited by 477
Shuin, T., Kondo, K., Torigoe, S., Kishida, T., Kubota, Y., Hosaka, M., Nagashima, Y., Kitamura, H., Latif, F., & Zbar, B. (1994) · PubMed · Cited by 471
The Genetic Basis of Cancer of the Kidney
LINEHAN, W. M., WALTHER, M. M., & ZBAR, B. (2003) · Journal of Urology · doi:10.1097/01.ju.0000096060.92397.ed · Cited by 470
Induction of Vascular Endothelial Growth Factor by Tumor Necrosis Factor α in Human Glioma Cells
Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H. A., Kohno, K., & Kuwano, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.45.28220 · Cited by 454
Effects of Thalidomide and Related Metabolites in a Mouse Corneal Model of Neovascularization
KENYON, B. M., BROWNE, F., & D'AMATO, R. J. (1997) · Experimental Eye Research · doi:10.1006/exer.1997.0292 · Cited by 440
Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., & Fidler, I. J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4562 · Cited by 440
Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000) · PubMed · Cited by 439
Vascular tumors in livers with targeted inactivation of the von Hippel–Lindau tumor suppressor
Haase, V. H., Glickman, J. N., Socolovsky, M., & Jaenisch, R. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1583 · Cited by 424
Discovery of a novel Raf kinase inhibitor.
Lyons, J. F., Wilhelm, S., Hibner, B., & Bollag, G. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080219 · Cited by 416
Stavri, G. T., Zachary, I. C., Baskerville, P. A., Martin, J. F., & Erusalimsky, J. D. (1995) · Circulation · doi:10.1161/01.cir.92.1.11 · Cited by 395
Kourembanas, S., Hannan, R. L., & Faller, D. V. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114759 · Cited by 386
Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M. M. F., Crossey, P. A., Richards, F. M., Cairns, P., Affara, N. A., Ferguson-Smith, M. A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.12.2169 · Cited by 373
Developmental roles of platelet‐derived growth factors
Betsholtz, C., Karlsson, L., & Lindahl, P. (2001) · BioEssays · doi:10.1002/bies.1069 · Cited by 372
Margolin, K., Gordon, M. S., Holmgren, E., Gaudreault, J., Novotny, W., Fyfe, G., Adelman, D., Stalter, S., & Breed, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.851 · Cited by 364
Inhibition of tumor angiogenesis mediated by cartilage.
Brem, H., & Folkman, J. (1975) · The Journal of experimental medicine · doi:10.1084/jem.141.2.427 · Cited by 359
Wiesener, M. S., Münchenhagen, P., Berger, I., Morgan, N. V., Roigas, J., Schwiertz, A., Jürgensen, J. S., Gruber, G., Maxwell, P. H., Löning, S. A., et al. (2001) · PubMed · Cited by 356
高橋, 敦. (1994) · Medical Entomology and Zoology · doi:10.11501/3101325 · Cited by 352
Murphy, A. N., Unsworth, E. J., & Stetler‐Stevenson, W. G. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041570219 · Cited by 351
Eisen, T., Boshoff, C., Mak, I., Sapunar, F., Vaughan, M. M., Pyle, L., Johnston, S. R. D., Ahern, R., Smith, I. E., & Gore, M. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1004 · Cited by 338
Slaton, J. W., Perrotte, P., Inoue, K., Dinney, C. P., & Fidler, I. J. (1999) · PubMed · Cited by 337
Drevs, J., Hofmann, I., Hugenschmidt, H., Wittig, C., Madjar, H., Müller, M., Wood, J. M., Martiny‐Baron, G., Unger, C., & Marmé, D. (2000) · PubMed · Cited by 308
Kim, K. J., Li, B., Houck, K., Winer, J., & Ferrara, N. (1992) · Growth Factors · doi:10.3109/08977199209023937 · Cited by 306
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 303
Dinney, C. P., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., BUCANA, C. D., & Fidler, I. J. (1998) · PubMed · Cited by 271
Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. C. M., & Maher, E. R. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-# · Cited by 270
Kuwabara, K., Ogawa, S., Matsumoto, M., Koga, S., Clauss, M., Pinsky, D. J., Lyn, P., Leavy, J., Witte, L., & Joseph-Silverstein, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.10.4606 · Cited by 251
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
Pause, A., Lee, S., Lonergan, K. M., & Klausner, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.993 · Cited by 238
Dvorak, H. F., Orenstein, N. S., Carvalho, A. C., Churchill, W. H., Dvorak, A. M., Galli, S. J., Feder, J., Bitzer, A. M., Rypysc, J., & Giovinco, P. (1979) · The Journal of Immunology · doi:10.4049/jimmunol.122.1.166 · Cited by 230
Huang, J., Frischer, J. S., Serur, A., Kadenhe, A., Yokoi, A., McCrudden, K. W., New, T., O'Toole, K., Zabski, S., Rudge, J. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432908100 · Cited by 227
Brauch, H. B., Weirich, G., Brieger, J., Glavač, D., Rödl, H., Eichinger, M., Feurer, M., Weidt, E. J., Puranakanitstha, C., Neuhaus, C., et al. (2000) · PubMed · Cited by 223
Schraml, P., Struckmann, K., Hatz, F., Sonnet, S., Kully, C., Gasser, T., Sauter, G., Mihatsch, M. J., & Moch, H. (2002) · The Journal of Pathology · doi:10.1002/path.1034 · Cited by 220
Goad, D. L. (1996) · Endocrinology · doi:10.1210/en.137.6.2262 · Cited by 217
Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 196
Kondo, K., Yao, M., Yoshida, M., Kishida, T., Shuin, T., Miura, T., Moriyama, M., Kobayashi, K., Sakai, N., Kaneko, S., et al. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10054 · Cited by 196
NA, X. I., WU, G., RYAN, C. K., SCHOEN, S. R., di’SANTAGNESE, P. A., & MESSING, E. M. (2003) · Journal of Urology · doi:10.1097/01.ju.0000074870.54671.98 · Cited by 194
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
Wang, T., Horng, S., Chang, C., Wu, H., Tsai, Y., Wang, H., & Soong, Y. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3300 · Cited by 187
de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1387 · Cited by 187
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann, B., Karumanchi, S. A., Cohen, H. T., & Sukhatme, V. P. (1998) · PubMed · Cited by 170
Motzer, R. J., Amato, R. J., Todd, M. B., Poo, W.-J., Cohen, R. B., Baselga, J. M., Muss, H. B., Cooper, M. R., Yu, R., Ginsberg, M. S., et al. (2003) · Investigational New Drugs · doi:10.1023/a:1022928612511 · Cited by 154
Cancer and Leukemia Group B 90206
Rini, B. I., Halabi, S., Taylor, J., Small, E. J., Schilsky, R. L., & for the Cancer Leukemia Group B (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0605 · Cited by 153
Self-citationVascular endothelial growth factor expression is increased in renal cell carcinoma.
Nicol, D. L., Hii, S.-I., Walsh, M. D., Teh, B. T., Thompson, L. C., Kennett, C., & Gotley, D. C. (1997) · PubMed · Cited by 150
Crossey, P. A., Foster, K., Richards, F. M., Phipps, M. E., Latif, F., Tory, K., Jones, M. H., Bentley, E., Kumar, R., Lerman, M., et al. (1994) · Human Genetics · doi:10.1007/bf00218913 · Cited by 148
Tomisawa, M., Tokunaga, T., Oshika, Y., Tsuchida, T., Fukushima, Y., Sato, H., Kijima, H., Yamazaki, H., Ueyama, Y., Tamaoki, N., et al. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00278-0 · Cited by 147
Gallou‐Kabani, C., Joly, D., JEAN, A. M., Staroz, F., Martin, N., Tarlet, G., Orfanelli, M.-T., Bouvier, R., Droz, D., tien, Y. C., et al. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(1999)13:6<464::aid-humu6>3.0.co;2-a · Cited by 144
Couch, V., Lindor, N. M., Karnes, P. S., & Michels, V. V. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.3.265 · Cited by 143
Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
Kruse, F. E., Joussen, A. M., Rohrschneider, K., Becker, M. D., & V�lcker, H. E. (1998) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s004170050106 · Cited by 142
Watanabe, Y., Lee, S. W., Detmar, M. J., Ajioka, I., & Dvorak, H. F. (1997) · Oncogene · doi:10.1038/sj.onc.1201033 · Cited by 141
Dosquet, C., Coudert, M., Lepage, É., Cabané, J., & Richard, F. (1997) · PubMed · Cited by 139
Randomized discontinuation trials: Utility and efficiency
Kopec, J. A., Abrahamowicz, M., & Esdaile, J. M. (1993) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(93)90163-u · Cited by 134
Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Berg, W. J., Ginsberg, M. S., Russo, P., Vuky, J., Yu, R., Bacik, J., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.302 · Cited by 133
Expression of vascular endothelial growth factor in renal cell carcinomas
Paradis, V., Lagha, N. B., ZEIMOURA, L., Blanchet, P., Eschwège, P., Ba, N., Benoît, G., Jardin, A., & Bédossa, P. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050458 · Cited by 125
Vascular Endothelial Growth Factor Expression is Increased in Renal Cell Carcinoma
Nicol, D. L., Hii, S.-I., Walsh, M. D., Teh, B. T., Thompson, L. C., Kennett, C., & Gotley, D. C. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)65028-6 · Cited by 115
Ma, W., Tessarollo, L., Hong, S., Baba, M., Southon, E. A., Back, T. C., Spence, S. E., Lobe, C. G., Sharma, N. D., Maher, G., et al. (2003) · PubMed · Cited by 113
The treatment of advanced renal cell cancer with high-dose oral thalidomide
Stebbing, J., Benson, C., Eisen, T. G., Pyle, L., Smalley, K. S. M., Bridle, H., Mak, I., Sapunar, F. J., A’Hern, R., & Gore, M. E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2025 · Cited by 109
Phase II trial of thalidomide in renal-cell carcinoma
Escudier, B. J., Lassau, N., Couanet, D., Angevin, E., Mesrati, F., Leborgne, S., Garofano, A., Leboulaire, C., Dupouy, N., & Laplanche, A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf213 · Cited by 109
Claffey, K. P., Abrams, K., Shih, S., Brown, L. F., Mullen, A., & Keough, M. P. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780212 · Cited by 108
Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes.
Moses, M. A., Sudhalter, J., & Langer, R. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.119.2.475 · Cited by 94
Thalidomide and a Thalidomide Analogue Inhibit Endothelial Cell Proliferation in vitro
Moreira, A. L., Friedlander, D. R., Shif, B., Kaplan, G., & Zagzag, D. (1999) · Journal of Neuro-Oncology · doi:10.1023/a:1006202700039 · Cited by 91
Bar‐Sagi, D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1441-1443.2001 · Cited by 89
Vascular endothelial growth factor expression, angiogenesis, and necrosis in renal cell carcinomas
Hemmerlein, B., Kugler, A., Özisik, R., Ringert, R.-H., Radzun, H., & Thelen, P. (2001) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280100464 · Cited by 86
Dupont, É., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pépin, M.-C., Wang, T., & Alaoui‐Jamali, M. A. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1014546909573 · Cited by 81
Igarashi, H., Esumi, M., Ishida, H., & Okada, K. (2002) · Cancer · doi:10.1002/cncr.10635 · Cited by 81
Hypoxia‐mediated regulation of gene expression in mammalian cells
Shih, S., & Claffey, K. P. (1998) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.1998.00088.x · Cited by 80
de Paulsen, N. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.031587498 · Cited by 78
Targeting Pdgf Receptors in Cancer Rationales and Proof of Concept Clinical Trials
George, D. J. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0081-0_12 · Cited by 77
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
Daliani, D., Papandreou, C. N., Thall, P. F., Wang, X., Perez, C. A., Oliva, R., Pagliaro, L. C., & Amato, R. J. (2002) · Cancer · doi:10.1002/cncr.10740 · Cited by 76
Béliveau, R., Gingras, D., Kruger, E. A., Lamy, S., Sirois, P., Simard, B., Sirois, M. G., Tranqui, L., Baffert, F., Beaulieu, É., et al. (2002) · PubMed · Cited by 65
Hernberg, M., Virkkunen, P. J., Bono, P., Ahtinen, H., Mäenpää, H. O., & Joensuu, H. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.536 · Cited by 64
Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound.
Gingras, D., Renaud, A., Mousseau, N., Beaulieu, É., Kachra, Z., & Béliveau, R. (2001) · PubMed · Cited by 63
Infrequent ras Oncogene Point Mutations in Renal Cell Carcinoma
Nanus, D. M., Mentle, I. R., Motzer, R. J., Bander, N. H., & Albino, A. P. (1990) · The Journal of Urology · doi:10.1016/s0022-5347(17)39905-6 · Cited by 63
Li, X., Liu, X., Wang, J., Wang, Z., Jiang, W., Reed, E., Zhang, Y., Liu, Y., & Li, Q. Q. (2003) · PubMed · Cited by 61
Dutcher, J. P., Atkins, M. B., Margolin, K. A., Weiss, G. R., Clark, J. I., Sosman, J. A., Logan, T. F., Aronson, F., & Mier, J. W. (2001) · Medical Oncology · doi:10.1385/mo:18:3:209 · Cited by 61
The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis.
Boivin, D., Gendron, S. P., Beaulieu, É., Gingras, D., & Béliveau, R. (2002) · PubMed · Cited by 57
Dupont, J., Schwartz, L., Koutcher, J. A., Spriggs, D. R., Gordon, M. S., Mendelson, D. S., Murren, J., Lucarelli, A., & Cedarbaum, J. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3009 · Cited by 56
Fox, S. B., Turley, H., Cheale, M., Blázquez, C., Roberts, H., James, N. H., Cook, N., Harris, A. L., & Gatter, K. C. (2004) · The Journal of Pathology · doi:10.1002/path.1520 · Cited by 55
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
Hainsworth, J. D., Sosman, J. A., Spigel, D. R., Schwert, R. C., Carrell, D. L., Hubbard, F. J., & Greco, F. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4502 · Cited by 55
A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma
Minor, D. R., Monroe, D., Damico, L. A., Meng, G., Suryadevara, U., & Elias, L. (2002) · Investigational New Drugs · doi:10.1023/a:1020669705369 · Cited by 48
Tsuchiya, N., Sato, K., Akao, T., Kakinuma, H., Sasaki, R., Shimoda, N., Satoh, S., Habuchi, T., Ogawa, O., & Kato, T. (2001) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.195.101 · Cited by 46
Matsumoto, K., Ohi, H., & Kanmatsuse, K. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000190275 · Cited by 43
Elaraj, D. M., White, D. E., Steinberg, S. M., Haworth, L. R., Rosenberg, S. A., & Yang, J. C. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200407000-00001 · Cited by 42
Gordon, M. S., Manola, J. B., Fairclough, D. L., Cella, D. F., Richardson, R., Sosman, J. A., Kasimis, B. S., Dutcher, J. P., & Wilding, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.4516 · Cited by 38
Effects of Thalidomide on Parameters Involved in Angiogenesis: An in vitro Study
Gelati, M., Corsini, E., Frigerio, S., Pollo, B., Broggi, G., Croci, D., Silvani, A., Boiardi, A., & Salmaggi, A. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1025618022921 · Cited by 22
(1995) · PubMed
Cited by
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Tabernero, J., Shapiro, G. I., LoRusso, P. M., Cervantes, A., Schwartz, G. K., Weiss, G. J., Paz-Ares, L., Cho, D. C., Infante, J. R., Alsina, M., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0429 · Cited by 698
Immunotherapy for advanced renal cell cancer
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001425.pub2 · Cited by 589
Retracted
Metadata
- Authors
- Rini, B. I., & Small, E. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-10
- Volume
- 23
- Issue
- 5
- Pages
- 1028-1043
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1980013575
- Cited by
- 408
- References
- 132
- FWCI
- 24.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.